Jump to content
SCLERO.ORG
Sclero Forums

Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis (SpA) changes in patients with psoriasis.


Recommended Posts

Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis (SpA) changes in patients with psoriasis.

 

Our study can imply that IL-17A is a valuable, useful and low–cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA psoriatic patients. PubMed, Int J rheumatologist Dis, 10/05/2020. (Also see Interleukins and Psoriasis and Psoriatic Arthritis)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Link to post
Share on other sites
  • Joelf unpinned this topic

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...